RxDoctor Payments Data

Laura Hart, MD

Family Medicine · Springhill, LANPI 1063831774

Payments from drug & device makers

$628in general payments, 2019–2025

Across 19 payments — averaging $33.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$252
  • Amgen$125
  • Lilly USA, LLC$48
  • Bayer$48
  • Kestra Medical Technology Services, Inc.$31
  • Novartis$30
  • plus $94 from 5 others

What the payments were for

  • Food & beverage$628100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$628 in reported general payments places this provider in the 45th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$14,590
Medicare patients
77
Services billed
174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide87$96,931
OzempicSemaglutide64$60,147
FarxigaDapagliflozin Propanediol31$36,310
JardianceEmpagliflozin27$25,591
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$22,068
JanuviaSitagliptin Phosphate24$21,194
LinzessLinaclotide33$20,807
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$19,206
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$15,740
EntrestoSacubitril/Valsartan11$8,904
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$8,225
Breo ElliptaFluticasone/Vilanterol15$6,886
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$5,918
Humulin N KwikpenInsulin Nph Human Isophane11$3,134
Albuterol Sulfate HfaAlbuterol Sulfate101$2,653

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$48$96,93187 claims
Novo NordiskOzempic$27$60,14764 claims
GSKTrelegy Ellipta, Breo Ellipta$13$28,95449 claims
AbbVieLinzess$20$20,80733 claims
NovartisEntresto$30$8,90411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Springhill

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →